Galapagos/€GLPG
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€GLPG
Sector
Primary listing
AEX
Employees
558
Headquarters
Website
Galapagos Metrics
BasicAdvanced
€2B
-
-€4.32
0.03
-
Price and volume
Market cap
€2B
Beta
0.03
52-week high
€32.64
52-week low
€20.00
Average daily volume
4.1K
Financial strength
Current ratio
8.079
Quick ratio
7.89
Long term debt to equity
0.229
Total debt to equity
0.395
Interest coverage (TTM)
-363.88%
Profitability
EBITDA (TTM)
-298.983
Gross margin (TTM)
39.41%
Net profit margin (TTM)
-103.14%
Operating margin (TTM)
-120.28%
Effective tax rate (TTM)
0.84%
Revenue per employee (TTM)
€490,000
Management effectiveness
Return on assets (TTM)
-5.11%
Return on equity (TTM)
-10.39%
Valuation
Price to revenue (TTM)
6.94
Price to book
0.74
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-6.409
Free cash flow yield (TTM)
-15.60%
Free cash flow per share (TTM)
-4.522
Growth
Revenue change (TTM)
5.43%
Earnings per share change (TTM)
-200.41%
3-year revenue growth (CAGR)
-18.28%
10-year revenue growth (CAGR)
12.91%
3-year earnings per share growth (CAGR)
51.90%
10-year earnings per share growth (CAGR)
9.03%
What the Analysts think about Galapagos
Analyst ratings (Buy, Hold, Sell) for Galapagos stock.
Bulls say / Bears say
On May 13, 2025, Galapagos’ Board decided to revisit its previously planned mid-2025 spin-off, founding Galapagos Cell Therapeutics and engaging Morgan Stanley as advisor to assess all strategic options. This reflects agile management and disciplined capital allocation aimed at maximizing shareholder value (Reuters).
Galapagos treated its first U.S. patient in the ATALANTA-1 Phase 1/2 trial for GLPG5101, targeting relapsed/refractory non-Hodgkin lymphoma, with mantle cell lymphoma chosen as its primary registrational indication. Pivotal development is expected to start in 2026, with initial approval projected for 2028, signaling promising near-term pipeline catalysts (Galapagos Press Release).
The launch of Galapagos Cell Therapeutics as an independent unit for all cell therapy activities, along with the appointments of Henry Gosebruch as CEO and Jérôme Contamine as Board Chair, tightens organizational focus on the key growth area of cell therapies (Galapagos Half-Year Update).
For the six months ended June 30, 2025, Galapagos’ operating loss rose sharply to €215.7 million from €71.3 million in the prior year, primarily due to €131.6 million in strategic reorganization and separation costs. This highlights ongoing unprofitability and elevated cash burn risk (Reuters).
Galapagos’ move to halt all small-molecule R&D programs—including its Phase 3–ready TYK2 inhibitor GLPG3667—means topline data will not be available until the first half of 2026. This postpones value creation and potential partnership milestones tied to these assets (Galapagos Annual Report).
The near-concurrent departures of CEO Paul Stoffels (retiring) and CFO/COO Thad Huston (leaving August 1, 2025) increase execution and governance risks during a crucial period of strategic reviews and pipeline progress (Galapagos Press Release).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Galapagos Financial Performance
Revenues and expenses
Galapagos Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of €2B as of October 17, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of October 17, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.